No current therapy for relapsing-remitting multiple sclerosis (MS) results in significant reversal of disability.
mately US $47 000 per patient 3, 4 to treat MS, no therapy approved by the US Food and Drug Administration (FDA) has been demonstrated to significantly reverse neurological disability or improve quality of life. [5] [6] [7] [8] [9] [10] [11] Autologous hematopoietic stem cell transplantation (HSCT) is a form of immune suppression but unlike standard immune-based drugs, it is designed to reset rather than suppress the immune system. [12] [13] [14] In a previous study, a nonmyeloablative regimen for patients with relapsing-remitting MS was associated with improvement in neurological disability and quality of life in 21 patients. 15 This report includes all patients from a single institution treated with a nonmyeloablative regimen with at least 6 months of follow-up, including the 21 patients previously reported. 15 
Methods

Patients
All patients who underwent HSCT for MS at Northwestern University (Chicago, Illinois) between July 2003 and February 2014 are included in this report. All patients signed informed consent and were treated and followed up identically per a study protocol approved by the Northwestern University institutional review board. Similar institutional review board approval was obtained for the reporting of patients treated off the study protocol. Race/ethnicity was recorded by the transplant team during the initial history and physical of each patient. Patients who were treated according to the study protocol underwent transplant and met all the following criteria: (1) had relapsing-remitting MS defined as acute relapses followed by partial or complete recovery and stable clinical manifestations between relapses, (2) fulfilled revised McDonald Diagnostic Criteria for MS, 16 (3) treatment was unsuccessful with at least 1 FDA-approved drug, (4) had an Extended Disability Status Scale (EDSS) score from 2.0 to 6.0, (5) were aged 18 to 55 years, and (6) during the preceding year, had either at least 2 relapses treated with a corticosteroid or 1 relapse treated with a corticosteroid and additional gadolinium-enhanced lesions on magnetic resonance imaging (MRI) scan at a separate time.
In addition, there were also patients treated off the study protocol on a compassionate basis for secondary-progressive MS, which was defined as a gradual progression of disability with or without superimposed relapses, or received HSCT for other reasons, including (1) brainstem, visual, or cognitive impairment with high risk of further paraplegic, quadriplegic, visional, or cognitive impairment, (2) EDSS score greater than 6.0, (3) treatment was unsuccessful with currently available FDA-approved drugs, (4) coexisting autoimmune or neurological disease, (5) allergy to gadolinium, (6) older than 55 years, and (7) tumefactive MS (tumor-like MRI appearance).
Most immune-modulation or suppression medications were stopped at the time of mobilization (collection of stem cells), except for natalizumab and fingolimod, which were discontinued 6 and 3 months, respectively, before transplant. After HSCT, patients did not receive immune-based therapies until clinical relapse or when new lesions were detected on an MRI scan.
Stem Cell Collection and Transplant Regimen
Peripheral blood stem cells were collected 10 days after patients received 2 g/m 2 of cyclophosphamide (administered intravenously) and 5 to 10 μg/kg of filgrastim (administered subcutaneously) daily beginning 5 days after receiving cyclophosphamide. The conditioning (immunoablative) regimen consisted of 50 mg/kg/d of cyclophosphamide (administered intravenously) 5 to 2 days before stem cell infusion (day 0) plus either 20 mg of alemtuzumab given 2 days before stem cell infusion (22 patients) or 0.5 mg/kg of thymoglobulin (administered intravenously) 5 days before stem cell infusion, 1.0 mg/kg 4 days before, and 1.5 mg/kg on 3 days, 2 days, and 1 day before stem cell infusion (129 patients).
In addition, 1000 mg of methylprednisolone was infused 30 minutes prior to each antithymocyte globulin infusion. On the day of stem cell infusion, oral prednisone was initiated with a dose of 60 mg/d given for 3 days, 40 mg/d for 2 days, 20 mg/d for 2 days, and 10 mg/d for 2 days. If fever developed, 250 mg of methylprednisolone was administered intravenously.
Supportive Care Guidelines
Blood products were irradiated and leukocytes were depleted. Filgrastim (5-10 μg/kg/d) was started on day 5 and continued until engraftment. Hyperhydration (150 mL/h of normal saline), diuretics, and intravenous mesna were continued until 24 hours after the last dose of cyclophosphamide. A Foley catheter was placed in patients with a history of urinary retention. Intravenous cefepime or piperacillin-tazobactam was started on the day of stem cell infusion and intravenous vancomycin was added for a febrile episode.
Oral daily acyclovir was started at hospital admission and continued for 1 year, oral fluconazole was started 2 days after HSCT and continued for 6 months, and oral trimethoprimsulfamethoxazole (3 times/wk) was started after platelet engraftment and continued for 6 months. Cytomegalovirus was monitored for 90 days and treated preemptively by switching from acyclovir to oral valganciclovir (900 mg twice/d) until a negative result was reached on quantitative polymerase chain reaction.
Study End Points
The primary end point was disability defined by the EDSS score (range, 0-10 in 0.5 increments). A decrease of 1.0 or greater is considered significant improvement and an increase of 1.0 or greater is considered significant progres-Sclerosis Functional Composite (MSFC) score, Short Form 36 (SF-36) quality-of-life score, new gadolinium-enhanced lesions on MRI scan, and total T2-weighted lesion volume on brain MRI scan. The NRS scores range from 0 to 100 19 ; a decrease of 10 or greater is considered significant progression and an increase of 10 or greater is considered significant improvement (eTable in the Supplement). [19] [20] [21] The MSFC measures leg function with the Timed 25-Foot Walk, arm coordination with the 9-Hole Peg Test, and cognitive function with the Paced Auditory Serial Addition Test 3, and reports an integrated score from individual z scores (eTable in the Supplement). 18 The SF-36 comprises 8 scales of functional health and well-being and perception of change in health on a scale of 0 to 100 with scores averaged to give a physical, mental, and total health score. Magnetic resonance imaging was obtained on a Siemens 1.5-Tesla scanner, which was used both before and after HSCT. Postcontrast T1-weighted imaging was delayed until 5 minutes after intravenous infusion of gadolinium (single dose of 0.1 mmol/kg). Patient positioning inside the scanner was standardized according to the University of Texas, Houston, MRI Analysis Center imaging acquisition manual. The T2 lesion volume, which correlates with clinical disease severity, was determined using the semiautomated contouring technique with Image J software (National Institutes of Health; http://rsbweb.nih.gov/ij/docs/faqs.html). The same observer (X.H.) marked all lesions, and an experienced reader (S.F.) blinded to MRI chronological order randomly reviewed MRI scans for accuracy.
Outcome parameters (MRI scan results and scores on the EDSS, NRS, MSFC, and SF-36) were measured at baseline, 6 months, 1 year, and then annually for 5 years. Thyroid function tests were performed if the patient was symptomatic. Between scheduled assessments, patients and their physicians were instructed to contact the study team to arrange unscheduled visits if any new symptoms were present.
Statistical Analysis
Two-tailed paired t tests (Microsoft Excel 2007) were used for comparison of prespecified primary and secondary outcome measures before and after HSCT. In post hoc analyses, a repeated-measures, mixed-effects model (SAS version 9.4; SAS Institute Inc) was used to calculate the least-squares means and SDs for change in EDSS score, adjusted for disease duration (>10 years or <10 years), type of MS (secondary-progressive vs relapsing-remitting), and presence of fever during transplant. Trends across time were examined by entering time into the model.
Differences between groups were assessed with the logrank test. If significant effects were found at the 5% level, they were fit in a multivariate Cox regression model. SAS PROC MIXED was used to build repeated-measures, mixed-effects Kaplan-Meier analysis was used to estimate relapse-free, progression-free, and disease activity-free survival. The MSFC and z scores were calculated in accordance with the Administrative and Scoring Manual.
23 Secondary outcomes were exploratory and not analyzed for association or interaction with disease duration, type, age, or fever during treatment, and were not adjusted for multiple comparisons.
Results
Of 151 patients who received HSCT during the study period, 123 had relapsing-remitting MS and 28 had secondaryprogressive MS. A total of 55 patients were treated on the study protocol. Ninety-six patients were treated off the study protocol on a compassionate basis for any of the following reasons: (1) had secondary-progressive MS (n = 28); (2) denied insurance for being entered into the trial (n = 18); (3) had brainstem, visual, or cognitive impairment with high risk of further paraplegic, quadriplegic, visional, or cognitive impairment (n = 15); (4) had an EDSS score of greater than 6.0 (n = 15); (5) experienced treatment failure with available FDAapproved drugs (n = 12); (6) had a coexisting autoimmune or neurological disease (n = 4); (7) had an allergy to gadolinium (n = 2); (8) were older than 55 years (n = 1); or (9) had tumefactive MS (n = 1). Of these 151 patients, 6 patients were not included in outcome analysis because 1 had nonreproducible neurological findings, 1 patient was lost to follow-up 1 year after HSCT, and 4 patients have not returned for complete assessment. The median age was 37 years (mean, 36 years; range, 18-60 years). The median duration of disease from time of diagnosis was 61 months (mean, 80 months; range, 9-264 months). Prior use of immune-modulation or suppression medications, the number of clinical relapses during the year prior to treatment, EDSS score at enrollment, and the number of gadolinium-enhanced lesions on baseline MRI scan appear in Table 1 .
Engraftment and Toxicity
The median day of engraftment (white blood cell count >1.0 × 10 9 /L) was day 10 (95% CI, 9.36-9.70) and the median day of hospital discharge was day 10 (95% CI, 10.21-10.75). The median number of platelet transfusions was 2.60 (95% CI, 2.21-2.99) and red blood cell transfusions was 2.00 (95% CI, 1.86-2.52). Twelve patients had positive rectal cultures for vancomycin-resistant enterococcus at the time of admission, and 2 patients had positive nasal cultures for methicillinresistant Staphylococcus aureus at admission. Only 1 patient had a positive blood culture identified as coagulase-negative staphylococcus. Four patients had diarrhea that tested positive for Clostridium difficile. Patients were followed up for a median of 2 years (mean, 2.5 years; range, 6 months-5 years) and the final follow-up date was June 2014. There were no treatmentrelated deaths and no early or late infectious cases of fungal, Pneumocystis jirovecii, cytomegalovirus, Epstein-Barr virus, or JC virus. Four patients developed late reactivation of dermatomal zoster, which was treated with oral acyclovir. Immune-mediated thrombocytopenia (ITP) developed in 3 of 22 (14%; 95% CI, 3%-35%) patients treated with alemtuzumab compared with 4 of 129 (3.1%; 95% CI, 0.9%-7.8%) patients treated with antithymocyte globulin (P = .07). Drug-free remission of ITP occurred in all cases after transient treatment with corticosteroids and intravenous immunoglobulin or rituximab. Hypothyroidism was present in 9 patients (6.2%; 95% CI, 2.9%-11.4%) before receiving HSCT. After transplant, 7 additional patients developed hypothyroidism or hyperthyroidism. For patients with normal thyroid function before HSCT, thyroid dysfunction developed posttransplant in 2 of 20 treated with alemtuzumab (9%; 95% CI, 1%-32%) and 5 of 122 treated with antithymocyte globulin (4.0%; 95% CI, 1.3%-9.3%) (P = .26). The incidence rate of posttransplant immune dysfunction (ITP, hypothyroidism, or hyperthyroidism) was 22.7% (95% CI, 7.8%-45.4%) in 5 of 22 patients receiving alemtuzumab compared with 6.9% (95% CI, 3.2%-12.7%) in 9 of 129 patients receiving antithymocyte globulin (P = .03).
During hospitalization for HSCT, 1 patient was incidentally found to have a preexisting localized adrenal carcinoma. No posttransplant cancers occurred in patients treated with cyclophosphamide and antithymocyte globulin. Two patients treated with cyclophosphamide and alemtuzumab developed cancer; one had breast in situ ductal carcinoma 3 years posttransplant and the other (who had also received mitoxantrone) developed lymphoma 5 years posttransplant.
Primary End Point
Transplant was associated with significant improvement in the EDSS score ( Table 2 ). The EDSS score improved significantly for the entire group (P < .001 at all time intervals except 5 years, which was P = .009) from a pretransplant median score of 4.0 to 3.0 at 6 months, 1 year, and 2 years and to 2.5 at 3, 4, and 5 years (Table 2 and Figure 1) . A general decrease in EDSS score over time posttransplant was observed (P < .001). The proportion of patients with a 1.0 or greater change in EDSS score was 51% (95% CI, 41%-61%) in 57 of 112 patients with an indication of improvement at 1 year and 10% (95% CI, 5%-20%) in 19 of 112 patients with an indication of progression; 50% (95% CI, 39%-61%) in 41 of 82 for improvement at 2 years and 11% (95% CI, 5%-21%) in 9 of 82 for progression; 50% (95% CI, 37%-63%) in 32 of 64 for improvement at 3 years and 11% (95% CI, 2%-22%) in 7 of 64 for progression; 64% (95% CI, 46%-79%) in 23 of 36 for improvement at 4 years and 8% (95% CI, 4%-34%) in 3 of 36 for progression; and 52% (95% CI, 32%-71%) in 14 of 27 for improvement at 5 years and 15% (95% CI, 5%-20%) in 4 of 27 for progression.
Secondary End Points
Treatment-related mortality was 0% and overall survival was 99.3%. The 1 death that occurred 30 months after HSCT was related to hypertensive cardiovascular disease. The KaplanMeier estimated relapse-free survival was 89% (95% CI, 81%-94%) at 2 years and 80% (95% CI, 69%-88%) at 4 years; progression-free survival was 92% (95% CI, 85%-96%) and 87% (95% CI, 78%-93%), respectively; and disease activity-free survival was 80% (95% CI, 70%-86%) and 68% (95% CI, 56%-77%) (Figure 2) .
Receipt of HSCT was associated with significant improvement in the NRS and MSFC component scores ( Table 3 ). The NRS impairment score improved significantly from a pretransplant median of 74 to 83 at 6 months, 85 at 1 year, 88 at 2 years, 90.5 at 3 years, 87.5 at 4 years, and 85 at 5 years. A general increase in NRS score (P < .001) over time The number of gadolinium-enhanced lesions on brain MRI scan decreased significantly (P < .001) at all posttransplant time points. The mean number of gadolinium-enhanced lesions was 3.22 at 3 to 6 months before HSCT, 2.57 within 3 months of HSCT, 0.01 at 6 months, 0.13 at 1 year, 0.07 at 2 years, 0.24 at 3 years, 0.67 at 4 years, and 0.08 at 5 years posttransplant. Brain T2 lesion volume decreased significantly between the pretransplant MRI scan and the most recent posttransplant MRI scan (eFigure 1 in the Supplement). With a mean follow-up of 27 months available for 128 patients with complete pretransplant and posttransplant MRI scans, the median T2 lesion volume decreased by 33% from a median of 8 [20] ; 95% CI, 61-68) (P < .001).
Post Hoc Analysis
Post hoc analysis showed that patients with relapsingremitting MS (n = 118), duration of disease of 10 years or shorter (n = 113), and those without sustained fever (defined as fever present on 3 readings at least 4 hours apart during a 24-hour period) during HSCT (n = 106) had significant improvements in EDSS score (eFigure 2 in the Supplement). Scores on the EDSS did not improve significantly for patients with secondaryprogressive MS (n = 27), in those with a disease duration of longer than 10 years (n = 32), or in those with sustained peritransplant fever of greater than 38.5°C (n = 31) (eFigure 2 in the Supplement). In the mixed-effects analysis, both the difference in duration of disease (>10 years vs ≤10 years) and type of disease (secondary-progressive MS vs relapsing-remitting MS) were associated with a significantly (P = .05) increased posttranspant EDSS score. Sex, age, baseline EDSS score, and prior number of immune drugs were not significantly associated with posttransplant EDSS scores.
Discussion
In this cohort of patients with MS undergoing HSCT, the EDSS score improved (decreased by ≥1.0 point), with 50% and 64% of patients demonstrating improvement at 2 years and 4 years, Because the minimal EDSS increment for scoring an individual patient is 0.5 and no previous study, to our knowledge, has demonstrated a decrease in EDSS score by 0.5 or more (improvement), a 1.0 decrease in EDSS score (improvement) in the treated patients, as shown herein and if substantiated in other studies, may set a benchmark for MS research based on reversal of disability rather than the traditional goal of slowing the accumulation of disability.
In our study, among the 132 patients who had complete sets of SF-36 questionnaires completed prior to HSCT and at their most recent evaluation after HSCT (median follow-up of 2 years), the SF-36 scores improved significantly (by 15 points for physical health, 20 for mental health, and 19 for total health). In the AFFIRM and SENTINEL trials, the SF-36 mental and physical component scores improved in the active treatment groups by 2.0 points or less. 29 Although the quality-of-life improvements in these trials were statistically significant, it is generally accepted that a clinically significant difference in SF-36 score requires a minimal change of 5 points.
30
In our cohort of patients with MS, there was no treatment-related mortality and no early or late infectious cases of fungal, P jirovecii, cytomegalovirus, Epstein-Barr virus, or JC virus. Four patients developed late reactivation of dermatomal zoster, which was treated with oral acyclovir. In our trial, posttransplant immune dysfunction (ITP, hypothyroidism, and hyperthyroidism) occurred and was significantly more common with alemtuzumab (22.7%) compared with antithymocyte globulin (6.9%). Both MS and treatment of MS with alemtuzumab are associated with ITP 31-33 and thyroid dysfunction.
34
Myeloablative transplant regimens cause irreversible bone marrow failure, thus mandating hematopoietic stem cell reinfusion to recover. Although, depending on the regimen, they may be relatively safe as reported in the Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) trial, 35 the toxicity and late complications can be substantial with myeloablative regimens. 12 In contrast, nonmyeloablative regimens, as used herein, are designed for transient marrow suppression. Although not necessary for recovery, stem cell infusion shortens the interval of neutropenia and attendant complications. Patient selection is important in determining outcome. In the post hoc analysis, the EDSS score did not improve in patients with secondary-progressive MS or in those with disease duration longer than 10 years. In our study, baseline EDSS score, older age, or prior number of immune-modulation or suppression regimens were not associated with a worse outcome. However, these findings may not be generalizable because we preselected patients with active inflammation and excluded those with late secondary-progressive MS.
Fever is an unfavorable prognostic factor for neurological recovery in patients with neuronal injuries related to cardiopulmonary bypass, cardiac arrest, cerebral vascular accident, traumatic closed head injury, and subarachnoid hemorrhage. 36, 37 In MS, environmental heat is associated with acute pseudo-relapses and disabling fatigue. 38, 39 In the post hoc analysis in our study, sustained fever during hospitalization for HSCT was associated with higher disability several years later. Due to early implementation of corticosteroids in our standard of care to prevent fever, the number of patients with sustained peritransplant fever was small, which decreased the statistical power of fever as a factor in the mixed-effects analysis. This study has several important limitations. First, the study was conducted at a single academic institution, which may introduce the possibility for bias. However, all patients had clinical continuity with a local treating neurologist not affiliated with the study who would also identify relapses or need for additional treatment.
Second, a large number of patients were treated on a compassionate basis, rather than on the study protocol. Nevertheless, all patients had a diagnosis of relapsingremitting MS or secondary-progressive MS and were treated with a nonmyeloablative regimen and followed up in an identical manner. In addition, by reporting all patients (similar to registry data), our results illustrate the risks of treatment that are unique to different nonmyeloablative regimens, the importance of patient selection, and peritransplant factors that influence neurological outcome and help to define the subset of MS patients for which HSCT is potentially beneficial within the clinical heterogeneity of patients who are most likely to be referred and treated with HSCT.
Third, improvement in function in patients with MS may be in part a consequence of continuing recovery from earlier relapses. However, to our knowledge, no other therapy for relapsing-remitting MS has demonstrated significant and sustained improvement in disability and quality of life and sustained lack of new disease activity despite absence of posttransplant disease-modifying therapy.
